Antonio Llombart
Overview
Explore the profile of Antonio Llombart including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
566
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Garcia-Saenz J, Rodriguez-Lescure A, Cruz J, Albanell J, Alba E, Llombart A
Target Oncol
. 2025 Mar;
PMID: 40059257
No abstract available.
2.
Garcia-Saenz J, Rodriguez-Lescure A, Cruz J, Albanell J, Alba E, Llombart A
Target Oncol
. 2025 Jan;
PMID: 39806129
Metastatic triple-negative breast cancer has a poor prognosis and poses significant therapeutic challenges. Until recently, limited therapeutic options have been available for patients with advanced disease after failure of first-line...
3.
Conte P, Ciruelos E, Curigliano G, De Laurentiis M, Del Mastro L, Gennari A, et al.
Breast
. 2024 May;
76:103742.
PMID: 38772190
Introduction: Advancements in monoclonal antibodies, tyrosine kinase inhibitors, and antibody drug conjugates (ADCs) have notably enhanced outcomes for metastatic HER2-positive breast cancer patients. Despite the expanding treatment options and clinical...
4.
Vaz Batista M, Perez-Garcia J, Eiriz I, Gion M, Llombart A, Braga S, et al.
Ann Transl Med
. 2023 Nov;
11(11):398.
PMID: 37970592
No abstract available.
5.
Vaz Batista M, Perez-Gracia J, Eiriz I, Gion M, Llombart A, Braga S, et al.
Oncotarget
. 2023 Jul;
14:701-702.
PMID: 37417883
No abstract available.
6.
Donat-Vargas C, Guerrero-Zotano A, Lope V, Bermejo B, Casas A, Baena-Canada J, et al.
Eur J Clin Nutr
. 2022 Feb;
76(9):1343-1346.
PMID: 35194197
The Epi-GEICAM study comprises 1017 invasive BC cases matched with controls of similar age (49 ± 9 years) and residence. Diet and OO consumption were collected through a validated food...
7.
Lopez-Vega J, Alvarez I, Anton A, Illarramendi J, Llombart A, Boni V, et al.
Cancers (Basel)
. 2021 Jul;
13(14).
PMID: 34298725
This prospective, phase II study evaluated novel biomarkers as predictors of response to bevacizumab in patients with breast cancer (BC), using serial imaging methods and gene expression analysis. Patients with...
8.
Pascual T, Fernandez-Martinez A, Tanioka M, Vittoria Dieci M, Pernas S, Gavila J, et al.
Clin Cancer Res
. 2021 Feb;
27(11):3116-3125.
PMID: 33632929
Purpose: We do not yet have validated biomarkers to predict response and outcome within hormone receptor-positive/HER2-positive (HR+/HER2+) breast cancer. The PAM50-based chemo-endocrine score (CES) predicts chemo-endocrine sensitivity in hormone receptor-positive/HER2-negative...
9.
Gagliato D, Buzaid A, Perez-Garcia J, Llombart A, Cortes J
Cancers (Basel)
. 2020 Sep;
12(9).
PMID: 32882980
Treatment paradigms in advanced hormone receptor (HR)-positive breast cancer were substantially transformed with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) approval. The addition of these drugs to endocrine treatment profoundly...
10.
Martin M, Garcia-Saenz J, Manso L, Llombart A, Cassinello A, Atienza M, et al.
Future Oncol
. 2020 Aug;
16(33):2763-2778.
PMID: 32781837
The addition of CDK4 and 6 inhibitors (abemaciclib, palbociclib or ribociclib) to endocrine therapy, as first-line treatment or following progression after initial endocrine therapy, significantly increased progression-free survival, objective response...